Literature DB >> 12756083

Radiotherapy for t3 prostate cancer.

Andrew Bayley1, Mary K Gospodarowicz.   

Abstract

Throughout the past decade, significant improvements in optimizing the management of T3 prostate cancer have been made. Phase III randomized studies have demonstrated the superiority of combined hormone therapy and radiation therapy over radiation therapy alone. Radiotherapy dose escalation using conformal techniques has improved local control and lowered toxicity. These advances have changed the approach to treatment of T3 prostate cancer from that directed at palliation of symptoms to earlier interventions directed at prolongation of survival. The contemporary role of radiation therapy in clinical T3 prostate cancer in the context of other treatment options is reviewed in this article.

Entities:  

Mesh:

Year:  2003        PMID: 12756083     DOI: 10.1007/s11934-003-0070-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  38 in total

1.  International trends in prostate-cancer mortality in the "PSA ERA".

Authors:  S E Oliver; M T May; D Gunnell
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

2.  Quiescence in R3327-G rat prostate tumors after androgen ablation.

Authors:  A Pollack; D L Joon; C S Wu; C Sikes; M Hasegawa; N H Terry; R A White; G K Zagars; M L Meistrich
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

3.  Status of radiation treatment of prostate cancer at Stanford University.

Authors:  M A Bagshaw; R S Cox; G R Ray
Journal:  NCI Monogr       Date:  1988

4.  Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.

Authors:  G K Zagars; A Pollack; L G Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-01       Impact factor: 7.038

Review 5.  Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer.

Authors:  M Roach
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

6.  Carcinoma of the prostate: results of radical radiotherapy (1970-1985).

Authors:  W Duncan; P Warde; C N Catton; A J Munro; R Lakier; T Gadalla; M K Gospodarowicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-05-20       Impact factor: 7.038

7.  Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.

Authors:  G K Zagars; D E Johnson; A C von Eschenbach; D H Hussey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-06       Impact factor: 7.038

8.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

Authors:  Colleen A Lawton; Michelle DeSilvio; Mack Roach; Valery Uhl; Robert Kirsch; Michael Seider; Marvin Rotman; Christopher Jones; Sucha Asbell; Richard Valicenti; Stephen Hahn; Charles R Thomas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-24       Impact factor: 7.038

9.  Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome.

Authors:  A L Zietman; R A Edelstein; J J Coen; R K Babayan; R J Krane
Journal:  Urology       Date:  1994-06       Impact factor: 2.649

10.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

Authors:  M J Zelefsky; S A Leibel; P B Gaudin; G J Kutcher; N E Fleshner; E S Venkatramen; V E Reuter; W R Fair; C C Ling; Z Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-06-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.